# Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study

Study · id `cardio:ct-nct07084259` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07084259](<https://clinicaltrials.gov/study/NCT07084259>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07084259

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 352 participants.

## Technical summary

Registry record NCT07084259. Randomized; no masking; primary purpose treatment. Start 2025-07 (anticipated); primary completion 2030-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 352 participants (planned count; ClinicalTrials.gov record NCT07084259, source copy `cardio:ctgov-nct07084259-2025-07-24`, retrieved 2026-10-26)
- Planned start: 2025-07 (anticipated) (ClinicalTrials.gov record NCT07084259, source copy `cardio:ctgov-nct07084259-2025-07-24`, retrieved 2026-10-26)
- Primary completion: 2030-06 (anticipated) (ClinicalTrials.gov record NCT07084259, source copy `cardio:ctgov-nct07084259-2025-07-24`, retrieved 2026-10-26)
- Completion: 2030-07 (anticipated) (ClinicalTrials.gov record NCT07084259, source copy `cardio:ctgov-nct07084259-2025-07-24`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07084259-2025-07-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study
- Acronym: HANYANG-PICK
- Condition: Coronary Artery Disease
- Intervention (Drug): PCSK9 inhibitor
- Intervention (Drug): Standard Lipid-Lowering Therapy
- Lead sponsor: Hanyang University Seoul Hospital
- Lead sponsor class: OTHER
- Collaborator: DOTTER Inc.
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Hanyang University Seoul Hospital (`cardio:org-hanyang-university-seoul-hospital`)

## Provenance

Content hash: 7dac41e22c19b72d23f317e88c11c90e22d8841abed8bb3cc8951ca2c345d515
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
